Ontology highlight
ABSTRACT:
SUBMITTER: Khanna D
PROVIDER: S-EPMC7213318 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Khanna Dinesh D Allanore Yannick Y Denton Christopher P CP Kuwana Masataka M Matucci-Cerinic Marco M Pope Janet E JE Atsumi Tatsuya T Bečvář Radim R Czirják László L Hachulla Eric E Ishii Tomonori T Ishikawa Osamu O Johnson Sindhu R SR De Langhe Ellen E Stagnaro Chiara C Riccieri Valeria V Schiopu Elena E Silver Richard M RM Smith Vanessa V Steen Virginia V Stevens Wendy W Szücs Gabriella G Truchetet Marie-Elise ME Wosnitza Melanie M Laapas Kaisa K de Oliveira Pena Janethe J Yao Zhen Z Kramer Frank F Distler Oliver O
Annals of the rheumatic diseases 20200501 5
<h4>Objectives</h4>Riociguat is approved for pulmonary arterial hypertension and has antiproliferative, anti-inflammatory and antifibrotic effects in animal models of tissue fibrosis. We evaluated the efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc) at high risk of skin fibrosis progression.<h4>Methods</h4>In this randomised, double-blind, placebo-controlled, phase IIb trial, adults with dcSSc of <18 months' duration and a modified Rodnan skin ...[more]